Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

113.54USD
13 Dec 2017
Change (% chg)

$-0.06 (-0.05%)
Prev Close
$113.60
Open
$113.94
Day's High
$114.90
Day's Low
$112.28
Volume
681,186
Avg. Vol
627,820
52-wk High
$149.17
52-wk Low
$96.18

Latest Key Developments (Source: Significant Developments)

Alexion reports Q3 non-GAAP earnings per share of $1.44
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alexion Pharmaceuticals Inc :Alexion reports third quarter 2017 results.Q3 non-GAAP earnings per share $1.44.Q3 GAAP earnings per share $0.35.Q3 revenue $859 million versus I/B/E/S view $864.5 million.Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S.Alexion Pharmaceuticals Inc - ‍provides updated 2017 guidance​.Alexion Pharmaceuticals Inc sees ‍ 2017 total revenues $3,475 million to $3,525 million​.Alexion Pharmaceuticals Inc sees ‍ 2017 GAAP earnings per share $2.00 to $2.35​.Alexion Pharmaceuticals Inc sees ‍ 2017 non-GAAP earnings per share $5.50 to $5.65​.Alexion Pharmaceuticals Inc - ‍2017 guidance assumes Soliris revenue impact of $80 million to $90 million from ALXN1210, other clinical trial recruitments.Alexion Pharma - ‍plans to initiate Single, PK-based Phase 3 study of ALXN1210 delivered subcutaneously once/ week to support registration in PNH, aHUS​.FY2017 earnings per share view $5.60 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.52 billion -- Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals says U.S. FDA approves Soliris for treatment of patients with GMG
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::FDA approves soliris® (eculizumab) for the treatment of patients with generalized myasthenia gravis (gmg).  Full Article

Alexion gets orphan drug designation for ALXN1007
Monday, 29 Aug 2016 

Alexion Pharmaceuticals Inc : European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD) .ALXN1007 is currently being evaluated in a phase 2 study in patients with newly diagnosed acute GI-GVHD.  Full Article

Alexion Pharmaceuticals-FDA recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode Island Manufacturing Facility
Monday, 8 Aug 2016 

Alexion Pharmaceuticals Inc : Fda recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode island manufacturing facility . FDA observations also pertain to monitoring of water systems . Based on current information, alexion anticipates that supply of soliris to patients will not be interrupted . FDA observations pertain to completion, closure of certain investigations, validation of surface sampling methods .Based on current information, does not anticipate material financial impact to resolve outstanding fda concerns.  Full Article

Alexion reports Q2 non-gaap EPS $1.13
Thursday, 28 Jul 2016 

Alexion Pharmaceuticals Inc : Sees FY non gaap earnings per share $4.50 to $4.65 . Sees FY non gaap total revenues $3,050 to $3,100 million . FY2016 earnings per share view $5.05, revenue view $3.06 billion -- Thomson Reuters I/B/E/S . Alexion reports second quarter 2016 results . Q2 non-gaap earnings per share $1.13 . Q2 gaap earnings per share $0.51 . Q2 revenue $753 million versus I/B/E/S view $742.7 million . Q2 earnings per share view $1.17 -- Thomson Reuters I/B/E/S . Sees FY gaap earnings per share $1.91 to $2.26 .Sees FY gaap total revenues $3,050 to $3,100 million.  Full Article

Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210
Friday, 10 Jun 2016 

Alexion Pharmaceuticals Inc : Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210 . Once-Monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase . Says no serious adverse events or study withdrawals were observed in either patient cohort . 2 patients experienced serious treatment-related adverse events and one patient had a grade 2 infusion-related reaction . Says six deaths were reported, none of which were considered related to treatment with ALXN1007 . Says were no grade 3 or higher non-serious adverse events related to treatment with ALXN1007 .Says one patient withdrew from study due to a treatment-emergent adverse event.  Full Article

Alexion announces topline results from Phase 3 regain study of eculizumab
Monday, 6 Jun 2016 

Alexion Pharmaceuticals Inc : Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG) . Primary endpoint of regain study missed statistical significance . Alexion continues to analyze data from regain study .Four patients receiving eculizumab (6.5 pct) discontinued treatment due to an adverse event.  Full Article

Alexion Pharmaceuticals says EC grants orphan drug designation to ALXN1210
Wednesday, 1 Jun 2016 

Alexion Pharmaceuticals Inc :European Commission has granted orphan drug designation to ALXN1210.  Full Article

Alexion Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 3 Feb 2016 

Alexion Pharmaceuticals Inc:Expects FY 2016 constant currency total product revenues of $3.170 to $3.220 billion.Expects FY 2016 constant currency earnings per share of $5.31 to $5.51.  Full Article

Elliott Management seeks changes at Alexion - NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals , is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.